Note Delveinsight market estimates don't (intentionally) include estimates for DMOAD for Knee OA.
This is an excerpt from their detailed report:We believe that, given long-term efficacy and stable safety data,Zilosul will add significant value to the treatment of Knee Osteoarthritis byaddressing certain critical unmet needs. Furthermore, if the company receives adisease-modifying osteoarthritis drug (DMOAD) designation, the drug will beeligible for a premium pricing, increasing the overall revenue of the product.However, as per our estimates, even if the drug does not receive DMOADdesignation and conservative pricing, the drug is expected to achieveapproximately USD 850 million by 2032 in the 7MM.
A multi-action DMOAD would create it's own market for knee OA that would be multiples of that of opioids, corticoids and viscosupplements.Think Humira on steroids
research reports and media, page-3493
-
- There are more pages in this discussion • 699 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.010(3.23%) |
Mkt cap ! $104.9M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.5¢ | 29.0¢ | $161.3K | 527.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10756 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 62010 | 3 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |